Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models

Odelia Katz, Matthew Stuible, Nathalia Golishevska, Lilach Lifshitz, Michel L Tremblay, Max Gassmann, Moshe Mittelman, and Drorit Neumann

Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
1Department of Medicine A, Sackler Faculty of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, 6 Weizmann Street, Tel Aviv 64239, Israel
2Goodman Cancer Centre and Department of Biochemistry, McGill University, 1160 des Pins West, Montreal, Quebec, Canada H3A 1A3
3Institute for Veterinary Physiology, Vetsuisse Faculty and Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 8057 Zurich, Switzerland

(Correspondence should be addressed to D Neumann; Email: histo6@post.tau.ac.il; M Mittelman; Email: moshemt@tasmc.health.gov.il)

Abstract

Erythropoietin (EPO) regulates proliferation and differentiation of erythroid precursor cells into erythrocytes. The last decade has revealed non-renal sites of EPO production and extrahematopoietic expression of the EPO receptor, thus suggesting that EPO has pleiotropic functions. Here, we addressed the interplay between EPO/glucose metabolism/body weight by employing a panel of relevant experimental murine models. The models focused on situations of increased EPO levels, including EPO-injected C57BL/6 and BALB/c mice, as well as transgenic mice (tg6) constitutively overexpressing human EPO, thus exposed to constantly high EPO serum levels. As experimental models for diabetes and obesity, we employed protein Tyr phosphatase 1B (PTP1B) knockout mice associated with resistance to diabetes (PTP1B−/−), and ob/ob mice susceptible to diabetes and obesity. The data presented herein demonstrate EPO-mediated decrease in blood glucose levels in all mice models tested. Moreover, in the ob/ob mice, we observed EPO-mediated attenuation of body weight gain and reduction of hemoglobin A1c. Taken together, our data bear significant clinical implications of EPO treatment in the management of a wide range of metabolic diseases, thus adding an important novel therapeutic potential to this pleiotropic hormone.

Journal of Endocrinology (2010) 205, 87–95

Introduction

The hematopoietic growth factor erythropoietin (EPO) is produced in the kidney in response to hypoxia, and stimulates erythropoiesis in the bone marrow (Krantz 1991, Spivak et al. 1991). Recombinant human EPO (rHuEPO) is an effective treatment for anemia of various etiologies, including anemias associated with renal failure (Winearls et al. 1986, Eschbach et al. 1989) and cancer-related diseases (Spivak 1994, Mittelman 1996). The presence of EPO receptors (EPO-R) on cells other than erythroid progenitors, including endothelial, myocardial, neural, and retinal cells, suggests that EPO has other biological functions in addition to erythropoiesis, reviewed in Arcasoy (2008). Hence, such functions include neuroprotection (Brines et al. 2004, Cilloni et al. 2004), anti-neoplastic activity (Mittelman et al. 2001, Katz et al. 2005), and improvement in congestive heart failure (Silverberg et al. 2002, Fiordaliso et al. 2005, Camici et al. 2007). We (Prutchi-Sagiv et al. 2006a,b, 2008, Ghezzi & Mengozzi 2007, Katz et al. 2007, Lifshitz et al. 2009), as well as others (Ghezzi & Mengozzi 2007), have found EPO-associated improvement in immunological functions.

In that respect, we have been attracted by the reports of EPO effects on glucose metabolism in hemodialysis patients (Borissova et al. 1993, Allegra et al. 1996), which are associated with elevated insulin sensitivity (Spaia et al. 2000, Tuzcu et al. 2004). EPO effects were also documented on the metabolism of proteins and lipids; however, the latter are still controversial (reviewed in Allegra et al. 1997). The ability to control glucose, protein, and lipid metabolism is of paramount value in clinical practice and is especially relevant in subjects with metabolic syndrome. Metabolic syndrome is common, affecting more than 30% of adults in the United States (Feldeisen & Tucker 2007), and is referred to as a ‘cluster of metabolic abnormalities’, including obesity, hyperglycemia, dyslipidemia, and hypertension (Chew et al. 2006). In the ‘modern’ world, diet and lifestyle contribute to the high incidence of obesity which is linked to increased risk for diabetes, cancer, and cardiovascular diseases, which leads to a reduction in life expectancy (Kolonin et al. 2004). In the last few decades, the prevalence of obesity and diabetes has been increasing rapidly (reviewed in Keller 2006). Consequently, the concern regarding obesity and its metabolic implications has directed intensive scientific effort.
concerning the adipose tissue, which is a major endocrine and signaling organ involved in a wide range of physiological responses, reviewed in Rosen & Spiegelman (2006).

The positive effect of rHuEPO treatment on glucose metabolism in hemodialyzed patients set the scene for exploring critically the interplay between EPO/glucose metabolism/body weight in the absence of any clinical problems. We have thus employed a panel of relevant murine models to investigate this issue. The models focused on situations of increased EPO levels, including EPO-injected CS7BL/6 and BALB/c mice, as well as transgenic mice constitutively overexpressing human EPO in an oxygen-independent manner (tg6; Ruschitzka et al. 2000, Vogel et al. 2003). EPO plasma levels in these mice are typically 10–12-fold higher than wt EPO levels (under normoxic conditions; Ruschitzka et al. 2000, Vogel et al. 2003). This elevation causes a doubling of their hematocrit from 40 to 80–90%, and up to 25% of the body weight is directed to the blood (Ruschitzka et al. 2000, Vogel et al. 2003). Expression of human EPO in these mice has been detected in the brain (where it most probably acts locally) as well as in the lung, from where it reaches circulation (Heinicke et al. 2006). As experimental models for diabetes and obesity, we employed phosphatase 1B (PTP1B or PTPN1 as listed in the MGI Database) knockout mice (Elchebly et al. 1999), and ob/ob mice susceptible to diabetes and obesity, reviewed in Houseknecht & Portocarrero (1998). Taken together, the data presented herein demonstrate EPO-associated decrease in blood glucose levels and attenuation of body weight gain, thus bearing significant clinical implications in the management of a wide range of metabolic diseases.

Materials and Methods

Mice

Female mice of the inbred strains BALB/c and CS7BL/6, aged 8 and 12 weeks respectively, were obtained from the Tel-Aviv University Animal Breeding Center. Transgenic mice overexpressing HuEPO (tg6; Ruschitzka et al. 2000) aged 3–6 months were bred by us, and their wt littermates (CS7BL/6) were used as controls. Male ob/ob mice (CS7BL/6), aged 7 weeks, were obtained from Harlan (Jerusalem, Israel). Three-month-old male PTP1B−/− mice (BALB/c) were previously described (Elchebly et al. 1999). Mice were maintained on a standard rodent chow diet (Koffolk, Tel Aviv, Israel). All procedures were approved by the animal care committees at the Sackler Faculty of Medicine Tel-Aviv University, Israel and at McGill University, Canada.

Injected materials

EPO in the form of EPREX, rHuEPO, Epoetin alfa) was obtained from Cilag Ltd, Schaffhausen, Switzerland. Mice received three weekly injections (s.c.) of 180 U rHuEPO or diluent (control) for the duration of the experiment. Glucose in the form of d-glucose was obtained from Sigma. Insulin in the form of Actrapid HM (ge) was obtained from Novo Nordisk, Kfar Saba, Israel.

Food consumption

Food consumption was measured for 4 weeks. Pre-weighed food was provided to the mice, the remaining food was measured subsequently, and the average food consumption per week was calculated for each mouse.

Metabolic assays

Serum glucose levels were determined by Accu-Check Go glucometer (Roche). Hemoglobin A1c (HbA1c) concentration in the blood was measured with DCA2000 analyzer (Bayer). Serum insulin levels were measured using a commercial enzyme immunoassay kit (Mercodia, Uppsala, Sweden).

Glucose tolerance test

For this test, mice deprived of food for over 4 h received an i.p. injection of glucose (2 g/kg body weight). Blood samples were then obtained from the tail for glucose determination at the indicated times.

Statistical analysis

Results are expressed as the mean±S.E.M. All results were analyzed by Student’s unpaired two-tailed t-test. Values of P<0.05 were considered statistically significant.

Results

We first examined, under non-fasting conditions, the effect of constitutively 10–12-fold elevated EPO serum levels on blood glucose level of EPO overexpressing transgenic mice (tg6; Ruschitzka et al. 2000). As shown in Fig. 1A, tg6 mice are hypoglycemic as compared to their normal (wt) littermates. Hence, in the fed state, tg6 mice displayed 49% less glucose level in their blood compared to the wt. This finding raised the question of whether short exposure to EPO may also affect the blood glucose levels. We thus compared the effect of rHuEPO treatment on blood glucose levels in murine models that are associated with diabetes and obesity (Fig. 1B and C), as well as wt mice (Fig. 1D and E). In these experiments, mice were injected with rHuEPO (180 U), three times weekly on alternating days. We found that after 1 week of treatment, all rHuEPO-treated mice had lower blood glucose levels, and these levels were further reduced during the second week of treatment. Moreover, this reduction was also observed within the group of rHuEPO-treated mice as compared to their initial blood glucose levels.

To investigate the effect of EPO on glucose clearance, we performed a glucose tolerance test (GTT) in all mice (Fig. 2).
In rHuEPO-treated mice, the test was performed during the third week of treatment. Administration of a bolus of glucose to tg6 and rHuEPO-treated mice resulted in a more rapid clearance of glucose than was observed in wt and the control group receiving just the diluent, instead of rHuEPO. In tg6 mice, a prominent hypoglycemia was evident 15 min following the glucose injection.

In order to determine whether tg6 mice are particularly sensitive to insulin, we measured serum insulin levels at fed state and performed intraperitoneal insulin tolerance test (Fig. 3). The results show that tg6 mice have lower serum insulin levels compared to their wt littermates (Fig. 3A). It thus appears that tg6 mice are more insulin sensitive, because they maintained lower glucose levels with significantly reduced insulin concentrations. This was further substantiated based on the results of the insulin tolerance test (ITT). The results indicated a hypoglycemic response in tg6 mice 15 min after i.p. insulin injection (0.5 U/Kg body weight), a state that was evident at all time points. In contrast, wt mice had a hyperglycemic response at 15 min, followed by a hypoglycemic response at the later time points (Fig. 3B).

Based on these data, we assessed the ability of EPO to affect the glucose metabolism using HbA1c measurements. This test was based on the fact that in patients with diabetes, HbA1c levels reflect the blood glucose levels during the preceding period of several months (Rohlfing et al. 2002). We thus measured HbA1c in tg6 and rHuEPO-treated ob/ob mice (Fig. 4). Due to the rapid half life of circulating erythrocytes in mice, the test was performed in ob/ob mice during the third week of rHuEPO treatment. HbA1c was reduced by 18 and 15% in tg6 and rHuEPO-treated ob/ob mice respectively, compared to their relevant control groups. Furthermore, the decrease in ob/ob mice was evident already after a short rHuEPO treatment.

We next questioned whether EPO has any effect on the body mass. We measured the body weight of tg6 mice as compared to their wt littermates. As shown in Fig. 5A, the body weight of tg6 mice was lower than that of wt mice in both males and females. To determine whether these weight differences result from a decrease in food intake, we estimated the amount of food consumed by the mice (Fig. 5B). The results showed that food intake was actually
higher in tg6 mice than in wt mice. Hence, tg6 mice maintained low body weight, even when higher amounts of food were consumed. To further resolve the differences in body weight, we analyzed the weights of distinct tissues, including liver, muscle (gastrocnemius), epididymal fat, and spleen tissue (Fig. 6). Although histological examination of these organs revealed no overt differences, we found that tg6 mice had 42% less epididymal fat mass compared with their wt littermates. Differences in adipose tissues were also noted in the subcutaneous skin fat; tg6 mice had very thin skin with a thin layer of subcutaneous fat. However, the blood lipids profile of the tg6 mice did not differ from those of the wt littermates (data not shown).

To evaluate the clinical significance of these EPO effects on the body mass, we examined whether rhHuEPO treatment has any effect on the body mass in ob/ob mice. We thus measured the body weight gain and food consumption of ob/ob mice during 2 weeks of rhHuEPO or diluent injections. The number of mice in each group is indicated; solid and open squares indicate EPO- and diluent-injected mice respectively. Values depict mean±S.E.M.*P<0.03, **P<0.003.
Hence, while non-treated ob/ob gained less weight compared to the non-treated ob/ob the rHuEPO-treated resistance (Pothiwala et al. 1999). Most of these studies were performed on patients including the PTP1B and/or body weight. We measured these parameters under constant exposure to high EPO levels, as well as under short term exposure to EPO (EPO-injected mice). The transgenic murine model tg6 that overexpresses human EPO (Ruschitzka et al. 2000) was thus employed to determine the effects of long-term, constant exposure to high EPO levels. The EPO-injected mice included a) normal – wild-type C57BL/6 and BALB/c mice; b) PTP1B−/− mice that are resistant to both diabetes and obesity (Elchebly et al. 1999, Klaman et al. 2000); c) ob/ob mice as a model for obesity and diabetes (Pelleymonter et al. 1995, Muzzin et al. 1996).

The results showed that the tg6 mice that are continuously exposed to EPO were hypoglycemic, even under non-fasting conditions. This result gained support from the experiments in which EPO was administered to mice for a period of 2 weeks. Moreover, the effect of EPO on the reduction of glucose levels was evident already 1 week following EPO administration in all the experimental models tested, including the PTP1B−/− and ob/ob mice. This conclusion gained further support by the metabolic tests, namely GTT. EPO overexpression or administration led to improved glucose clearance in all the tested murine models. Finally, HbA1c measurements provide a surrogate marker for blood glucose levels during several months prior to the test and are routinely employed clinically for the management of diabetes (Rohlfing et al. 2002, Giugliano et al. 2008). In that respect, HbA1c levels were reduced in the rHuEPO-treated ob/ob mice, thus pointing to the clinical relevance of EPO treatment to improve glucose metabolism in diabetic subjects. The fact EPO therapy was found to improve glucose metabolism in maintenance hemodialysis patients, mainly by reduction of insulin resistance (Allegra et al. 1996). In rats, EPO treatment was also associated with lowered blood glucose levels, both in resting and under physical stress (Cayla et al. 1999).

In the current study, we explored the effect of EPO on glucose metabolism by employing a panel of murine experimental models. Each of these models enables a unique analysis of the in vivo effects of EPO on blood glucose and/or body weight. We measured these parameters under constant exposure to high EPO levels, as well as under short term exposure to EPO (EPO-injected mice).

**Discussion**

The present study deals with the emerging concept that EPO is a pleiotropic hormone, acting also beyond its role in erythropoiesis (Krantz 1991). Previous reports have documented an effect of EPO on reduction of blood glucose levels (Allegra et al. 1996, Cayla et al. 1999, Rasic-Milutinovic et al. 2008). Most of these studies were performed on patients suffering from diabetes, a condition linked to insulin resistance (Pothiwala et al. 2009). Long-term rHuEPO

![Figure 4](image_url)  
**Figure 4** EPO-associated reduction in hemoglobin A1c. Groups of ob/ob mice were injected with rHuEPO or with diluent (control), three times weekly on alternating days for 3 weeks. HbA1c was measured in the sera of the ob/ob mice (n=5 and 6 for rHuEPO-treated and diluent-treated mice respectively) and in the tg6 mice and their wt littermates (n=4 and 3tg6 and wt mice respectively). Values depict mean ±S.E.M. *P<0.03, **P=0.001.

The results indicated that rHuEPO-treated ob/ob mice gained less weight compared to the non-treated ob/ob mice. Hence, while non-treated ob/ob mice had 24% weight gain, the rHuEPO-treated ob/ob mice had only 17% weight gain (P<0.004), in spite of the fact that there was no difference in food intake between these groups.

Taken together, our data indicate that EPO has effects on glucose homeostasis, insulin sensitivity, and body mass, pointing to potential benefits to diabetic and obese patients.

![Figure 5](image_url)  
**Figure 5** Reduced weight despite higher food consumption in tg6 mice. Body weight and food consumption of tg6 mice (4 months old), as compared to their wt littermates. (A) Body weight of female tg6 mice and their wt littermates (n=17 (tg6) and 19 (wt) mice/group) and of male tg6 mice and their wt littermates (n=8 (tg6) and 6 (wt) mice/group), *P=0.02, **P<0.004. (B) Weekly food consumption of female and male tg6 mice and their wt littermates, as calculated over a period of 4 weeks. Results are expressed as grams of food/mouse per week. n=5 Mice/group. Values depict mean weekly consumption of food per mouse ±S.E.M. *P<0.004.
that the decrease in HbA1c was observed as early as 3 weeks following EPO administration could result from the rapid metabolism characteristic of the mice (Wickler & Gleeson 1993), thereby differing from the profile of HbA1c response in human subjects (Bloomgarden 2006). Notably, the decrease in HbA1c in the tg6 mice was in the same range as in the EPO-injected \textit{ob/ob} mice, demonstrating that long-term as well as short-term exposures to EPO had a similar effect on this parameter, manifested in sustained levels of the HbA1c within the normal range.

What could be the mechanisms of EPO effects on blood glucose levels?

Figure 7  EPO administration attenuates weight gain in \textit{ob/ob} mice. Weight gain (A) and food consumption (B) of \textit{ob/ob} mice injected with EPO or with diluent (control). Body weight is presented as percentage change from initial body weight. Food consumption of individual \textit{ob/ob} mice was measured for a period of 2 weeks. Results are expressed as grams of food/mouse per week. \(n=6\) Mice/group. Values depict mean ± S.E.M. *\(P=0.03\), **\(P=0.003\).
The molecular mechanism by which EPO affects sensitivity to insulin is not yet resolved. EPO may operate via an increase in NO (Beleslin-Cokic et al. 2004), which is a powerful vasodilator as well as insulin sensitizer, reviewed in Marzo et al. (2008). Of note, tg6 mice express vast amounts of NO (Ruschitzka et al. 2000). In addition, the transcription factor CEBP/α (Cebpa as listed in the MGI Database) was found to decrease upon administration of EPO (Pinto et al. 2008). This transcription factor was found to be associated with energy homeostasis (Hackett 2008). Thus, for example, CEBP/α−/− mice do not display glycogen stores in the liver, they have elevated Epo-R mRNA in the liver, and they die of hypoglycemia shortly following birth (Wang et al. 1995, Zhang et al. 1997). Our observation that liver CEBP/α levels are reduced in the tg6 mice (data not shown) is in line with the possibility that the effects of EPO on glucose metabolism may also involve the reduction of this transcription factor.

Our results in the murine models led us to an insight into possible clinical applications. In that respect, we examined the effect of EPO treatment on the glucose levels and insulin consumption in a diabetic patient. Indeed, EPO treatment reduced the blood glucose levels and reduced the required doses of insulin (data not shown). These data are supported by a recent report on the effects of EPO on lowered insulin consumption and HbA1c in a diabetic patient with chronic kidney disease-induced anemia (Brown et al. 2009). These findings now call for an extensive clinical study on a larger scale of patients.

Concomitant with the effects of EPO on glucose levels and insulin sensitivity, we found that EPO administration or overexpression was associated with a decrease in body weight. This decrease is at least partially associated with reduced amount of fat tissue, especially evident in the leanness of the tg6 mice. Our results are in line with a recent publication demonstrating that targeted overexpression of EPO in muscle tissue of mice protected against diet induced obesity and increased metabolic parameters (Hojman et al. 2009). In line with this observation is our finding that EPO is associated with attenuated body weight gain in the ob/ob mice, despite similar food intake as the diluent-treated mice. The precise mechanism underlying the decreased body weight has yet to be elucidated. It does not appear to be related to nausea with or without reduced food intake, since this parameter was tested and ruled out. An increased energy consumption or expenditure is thus a possible mechanism, related to the main findings of this study, i.e. reduced blood glucose levels associated with EPO.

To gain insight into the molecular mediators, we questioned whether regulation of PTP1B could explain these EPO-mediated effects on glucose metabolism. Our choice to focus on PTP1B leans on the finding that it is a pivotal down-regulator of insulin signaling (Elchelby et al. 1999, Rondinone et al. 2002, Boute et al. 2003, Waring et al. 2003, Isad et al. 2005) and that PTP1B−/− mice are resistant to obesity and diabetes (Elchelby et al. 1999, Klaman et al. 2000, Haj et al. 2005). Moreover, PTP1B was shown by us Cohen et al. (2004), and by others (Callero et al. 2007), to participate in downregulation of EPO signaling. Our present finding that EPO treatment culminated in reduction of blood glucose in the PTP1B−/− mice thus rules out the possibility that this EPO action is mediated via PTP1B.

Various aspects of EPO action in rodent models have been documented, including prevention of diabetes-induced podocyte damage (Schiffer et al. 2008), enhancement of wound healing (Galeano et al. 2004), and promotion of vascular cell viability (Chong et al. 2007). Taken together, our findings single out EPO as a potential novel glucose regulator.

The current study exemplifies an exciting potential application for EPO as an adjunct anti-diabetic/obesity drug to reduce blood glucose levels and attenuate weight gain especially where these are associated with low levels of hemoglobin. Obviously, introducing EPO for these indications would require additional basic research as well as clinical trials. The idea that EPO acts on glucose metabolism places this hormone in a new and most important area, with significant clinical applications in diabetes and obesity. These are currently critical health issues at the forefront of medical and social interest.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

The project was supported in part by a grant from the Chief Scientist’s Office of the Ministry of Health, Israel, by the Israel Cancer Association, by the Israeli Cancer Research Foundation (D N), and by the Swiss National Science Foundation (M G).

Acknowledgements

This work was performed in partial fulfillment of the requirements for PhD degree by Odelia Katz, Sackler Faculty of Medicine, Tel Aviv University, Israel.

References


Boute N, Boubekeur N, Lacasa D & Issad T 2003 Dynamics of the interaction between the insulin receptor and protein tyrosine-phosphatase 1B in living cells. EMBO Reports 4 313–319.


Chew GT, Gan SK & Watts GF 2006 Revisiting the metabolic syndrome. Current Opinion in Biomedical Research 12 194–204.


Haj FG, Zabolotny JM, Kim YB, Kahn BB & Neel BG 2005 Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B−/− mice. Journal of Biological Chemistry 280 15038–15046.


www.endocrinology-journals.org
Erythropoietin-mediated reduction in blood glucose • O Katz and others

Received in final form 18 December 2009
Accepted 8 January 2010
Made available online as an Accepted Preprint 8 January 2010


Silverberg DS, Wexler D, Blum M, Tchebner J, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M et al. 2002 The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clinical Nephrology 58 S37–S45.


